ANI Pharmaceuticals Inc (NASDAQ:ANIP) SVP James G. Marken Sells 8,907 Shares

Share on StockTwits

ANI Pharmaceuticals Inc (NASDAQ:ANIP) SVP James G. Marken sold 8,907 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $70.67, for a total value of $629,457.69. Following the completion of the sale, the senior vice president now directly owns 61,230 shares of the company’s stock, valued at approximately $4,327,124.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of ANIP stock opened at $69.68 on Wednesday. ANI Pharmaceuticals Inc has a 12-month low of $36.92 and a 12-month high of $74.00. The company has a market capitalization of $851.78 million, a P/E ratio of 15.11 and a beta of 2.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.92 and a quick ratio of 0.67.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.25. ANI Pharmaceuticals had a return on equity of 28.63% and a net margin of 6.58%. The business had revenue of $52.90 million during the quarter, compared to analyst estimates of $50.57 million. During the same period in the prior year, the company posted $1.32 EPS. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. Equities research analysts forecast that ANI Pharmaceuticals Inc will post 5.57 EPS for the current fiscal year.

Several equities research analysts have recently weighed in on ANIP shares. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 19th. Raymond James set a $73.00 price target on ANI Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, February 28th. BidaskClub upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $76.00 price target on the stock in a research report on Thursday, March 28th. Finally, ValuEngine upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $84.50.

Hedge funds have recently modified their holdings of the stock. Financial Gravity Wealth Inc. bought a new position in ANI Pharmaceuticals in the 1st quarter worth approximately $54,000. Quantamental Technologies LLC boosted its stake in ANI Pharmaceuticals by 169.4% during the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 542 shares in the last quarter. South Dakota Investment Council bought a new position in ANI Pharmaceuticals during the 4th quarter valued at $45,000. BNP Paribas Arbitrage SA boosted its stake in ANI Pharmaceuticals by 55,466.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 1,664 shares in the last quarter. Finally, Truvestments Capital LLC bought a new position in ANI Pharmaceuticals during the 1st quarter valued at $140,000. 63.92% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “ANI Pharmaceuticals Inc (NASDAQ:ANIP) SVP James G. Marken Sells 8,907 Shares” was posted by Tech Know Bits and is the property of of Tech Know Bits. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://techknowbits.com/2019/06/12/ani-pharmaceuticals-inc-anip-svp-james-g-marken-sells-8907-shares.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Read More: What is Compound Annual Growth Rate (CAGR)?

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.